drugset

drugset / Trial / NCT06248567

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

NCT06248567 ↗

Phase 1 Completed 16 enrolled Guangdong Raynovent Biotech Co., Ltd

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Timeline

Start: 2024-01-15
Primary completion: 2024-04-30
Completion: 2024-05-30

Publications

Li H, Yang X, Zhang J, Chen L, Zhou M, Li Y, Liu X, Huang J, Huang J. Pharmacokinetics, safety, and tolerability of onradivir in participants with severe renal impairment and matched healthy control participants. Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0046225. doi: 10.1128/aac.00462-25. Epub 2025 Aug 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onradivir	Small molecule	600 mg	Oral

Indications